ArticleMolecular medicine reports2017
Expression of cyclooxygenase-2 is correlated with lncRNA-COX-2 in cirrhotic mice induced by carbon tetrachloride.
Article in Molecular medicine reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 31 citations in OpenAlex.
- Validation of Baveno VII criteria for recompensation in patients with decompensated cirrhosis treated by laparoscopic splenectomy and azygoportal disconnection.Journal of gastroenterology · 2026Article
- miRNAs, lncRNAs, circRNAs and piRNAs in Nonalcoholic Fatty Liver Disease: Past, Present and Future.International journal of molecular sciences · 2025Review
- Advances of Long Non-Coding RNAs as Potential Biomarkers for Tuberculosis: New Hope for Diagnosis?Pharmaceutics · 2023Review
- Ameliorative effects of allogeneic and xenogenic bone marrow-derived mesechymal stem cells on carbon tetrachloride-induced rat liver injury and cirrhosis via modulation of oxidative stress, apoptosis, inflammation, and Nrf2 expression.American journal of translational research · 2023Article
- Noncoding RNA-mediated macrophage and cancer cell crosstalk in hepatocellular carcinoma.Molecular therapy oncolytics · 2022Review
- Mechanisms of Xiaochaihu Decoction on Treating Hepatic Fibrosis Explored by Network Pharmacology.Disease markers · 2022Article
- Celecoxib reduces hepatic vascular resistance in portal hypertension by amelioration of endothelial oxidative stress.Journal of cellular and molecular medicine · 2021Article
- Long non-coding RNAs in metabolic disorders: pathogenetic relevance and potential biomarkers and therapeutic targets.Journal of endocrinological investigation · 2021Review
- Dysregulation of HULC promotes contrast-induced nephropathy (CIN) via regulating signaling pathway of miRNA-512 and prostaglandin E1 (PGEScientific reports · 2020Article
- Noncoding RNAs in Nonalcoholic Fatty Liver Disease: Potential Diagnosis and Prognosis Biomarkers.Disease markers · 2020Review
- Lnc-TCL6 is a potential biomarker for early diagnosis and grade in liver-cirrhosis patients.Gastroenterology report · 2019Article
- Role of Non-Coding RNAs in the Progression of Liver Cancer: Evidence from Experimental Models.Cancers · 2019Review
- Suppressing growth and invasion of human hepatocellular carcinoma cells by celecoxib through inhibition of cyclooxygenase-2.Cancer management and research · 2019Article
- LincRNA Cox-2 Regulates Lipopolysaccharide-Induced Inflammatory Response of Human Peritoneal Mesothelial Cells via Modulating miR-21/NF-Mediators of inflammation · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple long non-coding RNAs (lncRNAs) have been demonstrated to be involved in liver disease. Increased cyclooxygenase-2 (COX‑2) levels have also been reported to be involved in the progression of liver cirrhosis. In the present study, the correlations between lncRNA‑COX‑2 RNA expression levels, COX‑2 mRNA expression levels and liver fibrosis were examined. Liver fibrosis was induced by intraperitoneal injection of carbon tetrachloride (CCl4) in mice for 2 months (CCl4‑2M) or 3 months (CCl4‑3M). Liver histopathological evaluation was conducted using hematoxylin and eosin and Masson trichrome staining. Hepatic expression of COX‑2 and lncRNA‑COX‑2 was evaluated by reverse transcription‑quantitative polymerase chain reaction and immunohistochemical staining. Compared with the control group, fibrotic areas were increased four and nine times in the CCl4‑2M group and the CCl4‑3M group, respectively. LncRNA-COX-2 and COX‑2 upregulation were observed in the cirrhotic liver. COX‑2 mRNA expression levels and lncRNA-COX-2 RNA expression levels were significantly positively correlated with the fibrotic area. In addition, COX‑2 mRNA expression was significantly positively correlated with lncRNA‑COX‑2 expression. These results suggest that expression of COX‑2 and lncRNA‑COX‑2 increased with the progression of liver fibrosis. LncRNA-COX-2 may potentially be considered as a novel therapeutic target for liver fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.